A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2
Buter, J.; Sleijfer, D.T.; van der Graaf, W.T.; de Vries, E.G.; Willemse, P.H.; Mulder, N.H.
Seminars in Oncology 20(6 Suppl. 9): 16-21
1993
ISSN/ISBN: 0093-7754 PMID: 8284687 Document Number: 421003
Document emailed within 1 workday
Related Documents
Lissoni, P.; Rovelli, F.; Baiocco, N.; Tangini, G.; Fumagalli, L. 2001: A phase Ii study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone Anticancer Research 21(1b): 777-779Fisher, R.I.; Rosenberg, S.A.; Fyfe, G. 2000: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer Journal from Scientific American 6(Suppl): S55-S57
Voravud, N.; Sriuranpong, V.; Lertsaguansinchai, P. 2000: Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma Journal of the Medical Association of Thailand 83(2): 123-128
Negrier, S.; Maral, J.; Drevon, M.; Vinke, J.; Escudier, B.; Philip, T. 2000: Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe Cancer Journal from Scientific American 6(Suppl): S93-S98
Morita, T.; Yonese, Y.; Minato, N. 1987: In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma Journal of the National Cancer Institute 78(3): 441-450
Bukowski, R.M.; Sharfman, W.; Murthy, S.; Rayman, P.; Tubbs, R.; Alexander, J.; Budd, G.T.; Sergi, J.S.; Bauer, L.; Gibson, V. 1991: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma Cancer Research 51(16): 4199-4205
Shi, B.; Nakazawa, H.; Ryoji, O.; Goya, N.; Ito, F.; Koga, S.; Okuda, H.; Kobayashi, H.; Toma, H. 1998: Study on urinary levels of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha in patients with renal cell carcinoma Hinyokika Kiyo. Acta Urologica Japonica 44(3): 143-147
Motzer, R.J.; Nanus, D.M.; O'Moore, P.; Scher, H.I.; Bajorin, D.F.; Reuter, V.; Tong, W.P.; Iversen, J.; Louison, C.; Albino, A.P. 1992: Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression Cancer Research 52(20): 5775-5779
Jurincic-Winkler, C.; Horlbeck, R.; Klippel, K.F. 1993: Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer Wiener Klinische Wochenschrift 105(10): 271-276
Huang, T.; Song, X-shuang.; Zhang, Z-wei. 2013: Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases Zhonghua Yi Xue Za Zhi 93(24): 1903-1905
Shimura, H.; Hara, Y.; Ida, T. 1993: A case report of markedly effective recombinant interferon therapy in residual tumor of renal cell carcinoma Hinyokika Kiyo. Acta Urologica Japonica 39(3): 261-263
Atzpodien, J.; Poliwoda, H.; Kirchner, H. 1991: Alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients Seminars in Oncology 18(5 Suppl 7: 108-112
Tang, B.; Chi, Z.; Sheng, X.; Cui, C.; Si, L.; Kong, Y.; Li, S.; Mao, L.; Lian, B.; Wang, X.; Yan, X.; Guo, J. 2015: Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma Zhonghua Yi Xue Za Zhi 95(30): 2459-2461
Evans, W.K.; Shepherd, F.A.; Blackstein, M.E.; Osoba, D.; Taylor, D. 1985: Phase Ii evaluation of bisantrene in patients with advanced renal cell carcinoma Cancer Treatment Reports 69(6): 727-728
Wada, T.; Nishiyama, K.; Maeda, M.; Hara, S.; Tanaka, N.; Yasutomi, M.; Kurita, T. 1995: Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma Anticancer Research 15(4): 1581-1584
Imada, K.; Eto, M. 2019: Ⅱ. how Has the Treatment Outcomes for Advanced Renal Cell Carcinoma Improved in the 10 Years after Approval of Targeted Therapy ? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(1): 40-44
Lee, D.S.; White, D.E.; Hurst, R.; Rosenberg, S.A.; Yang, J.C. 1998: Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy Cancer Journal From Scientific American 4(2): 86-93
Nishio, Y.; Nishimura, K.; Hida, S.; Okada, Y.; Takeuchi, H.; Miyakawa, M.; Okada, K.; Yoshida, O. 1987: Results of radical nephrectomy for renal cell carcinoma. Report 1. Analysis according to the TNM staging system of the general rule for clinical and pathological studies on renal cell carcinoma Hinyokika Kiyo. Acta Urologica Japonica 33(3): 337-343
Taylor, S.A.; Von Hoff, D.D.; Baker, L.H.; Balcerzak, S.P. 1984: Phase Ii clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study Cancer Treatment Reports 68(6): 919-920
Adamson, W.; Egrie, J.C.; Browne, J.K.; Downing, M.R.; Eschbach, W. 1988: The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report Behring Institute Mitteilungen 1988(83): 188-192